Senseonics adds friends-and-family data sharing to CGM app in EMEA market

By Jonah Comstock

Implantable glucose sensor company Senseonics has launched a remote monitoring app for its users in Europe, the Middle East, and Africa, where its CGM system is distributed by Roche.

The app, called Eversense Now, allows users of the sensor to select up to five friends or family members to view their glucose data, which is updated every five minutes. The feature is available for iOS users at the moment, with plans for Android in the works.

"We are thrilled to bring this new product to people with diabetes, their families, and friends," Tim Goodnow, CEO and president of Senseonics, said in a statement. "The extra peace of mind and sense of community that comes when someone else can see your real-time glucose data is an important part of a comprehensive solution we want to offer to our customers."

Senseonic’s main offering is the Eversense XL CGM, a pill-sized implantable device that can last up to 180 days without need of replacement. It is now available in 13 countries, but the United States isn't one of them — thanks to a long wait for FDA clearance.

App connectivity isn't new for the company, which has always had the readings from the sensor sent to a small transmitter which then passes the data on to the user's phone. But the ability to share data with others is useful for many people with diabetes, whether its parents who want to keep a close eye on their children's glucose readings or business travelers who want their loved ones to have piece of mind while they're traveling. Up until now, the app could only send reports or snapshots to caregivers.

Notably, Dexcom has had some version of this feature since 2014 and has since improved it to work with both Android and Apple phones with no additional hardware.

Dexcom partner Tandem Diabetes Care, which makes a connected insulin pump that integrates with Dexcom's CGM, made its own announcement today about plans to enter the Canadian market in the second half of the year. The company has just submitted its medical device license application to the Canadian government.

"This application is another important step toward achieving our strategic goal of bringing the benefits of the t:slim X2 Insulin Pump to people outside of the United States," Kim Blickenstaff, president and CEO of Tandem Diabetes Care, said in a statement. "When available, the t:slim X2 will provide people in Canada a competitive choice in the durable insulin pump market, which we believe will be of particular interest as the only pump with Dexcom G5 Mobile CGM integration."